IFNG and leukemia: In an aggressive leukemia mouse model, we show that IFN‐γ gene therapy boosted anti‐leukemia immune responses, resulting in the elimination of more immunogenic subclones expressing surrogate antigens and selecting for more primitive disease variants that escape immune control.